Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Oncocyte Corp
(NQ:
OCX
)
3.000
+0.050 (+1.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Oncocyte Corp
< Previous
1
2
3
4
Next >
Oncocyte Reports It's Ready To Enter The $3.6 Billion Transplant Diagnostics Market In First Half Of 2022
May 05, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. The transplant diagnostics market encompasses blood tests,...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 20, 2022
Gainers
Via
Benzinga
2 Stocks Under $2 Insiders Are Aggressively Buying
April 19, 2022
Gold futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Via
Talk Markets
2 Stocks Under $2 Insiders Are Aggressively Buying
April 19, 2022
Gold futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around...
Via
Benzinga
4 Stocks Under $5 Insiders Are Aggressively Buying
April 18, 2022
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the...
Via
Benzinga
Earnings Scheduled For March 10, 2022
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 14, 2022
The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!
Via
InvestorPlace
Oncocyte And Thermo Fisher Report Teaming Up To Bring Precision Medicine To Cancer Patients Worldwide
April 12, 2022
Image provided by Thermo Fisher Scientific Inc. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
What 4 Analyst Ratings Have To Say About OncoCyte
March 18, 2022
OncoCyte (NASDAQ:OCX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2022
March 14, 2022
Upgrades Janney Montgomery Scott upgraded the previous rating for Enova International Inc (NYSE:ENVA) from Neutral to Buy. Enova International earned $1.61 in the fourth quarter,...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 10, 2022
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 14.8% to $1.55 during Thursday's after-market session. The company's market cap stands at $92.4 million. As per the press release, Q4...
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
Meet A Company Creating Diagnostic Solutions to Enhance Lung Cancer Treatment And Care
January 25, 2022
Photo by the National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be...
Via
Benzinga
52 Biggest Movers From Yesterday
January 20, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion. G...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles 150 Points; Yumanity Therapeutics Shares Plunge
January 19, 2022
Toward the end of trading Wednesday, the Dow traded down 0.45% to 35,210.04 while the NASDAQ fell 0.28% to 14,466.47. The S&P also fell, dropping, 0.29% to 4,563.94. The U.S....
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 19, 2022
Gainers Zogenix (NASDAQ:ZGNX) shares moved upwards by 67.2% to $26.15 during Wednesday's regular session. As of 12:30 EST, Zogenix's stock is trading at a volume...
Via
Benzinga
Mid-Day Market Update: US Stocks Turn Negative; Zogenix Shares Spike Higher
January 19, 2022
Midway through trading Wednesday, the Dow traded down 0.13% to 35,321.51 while the NASDAQ fell 0.53% to 14,430.41. The S&P also fell, dropping, 0.19% to 4,568.33. The U.S. has...
Via
Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
January 19, 2022
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares jumped 67.1% to $26.15 after the company announced it will be acquired by UCB for approximately $1.9 billion. Splash Beverage Group,...
Via
Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
January 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...
Via
Benzinga
65 Biggest Movers From Yesterday
January 19, 2022
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 18, 2022
Gainers DBV Technologies (NASDAQ:DBVT) sh...
Via
Benzinga
Benzinga Announces This Week's All Access Guests
January 18, 2022
Benzinga is thrilled to announce the guest lineup for our next All Access show, sponsored by TiiCKER, set to air Friday, January 21 at 9:15 am ET. The Lineup 9:20 am...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 29, 2021
Gainers Biofrontera (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
December 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
January 07, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:
Via
Benzinga
How Bad Are OncoCyte Corporation Common Stock's Earnings? | Return On Capital Employed
November 09, 2021
OncoCyte Corporation Common Stock (AMEX:OCX) brought in sales totaling $2.03 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 19.44%,...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
How Bad Are OncoCyte Corporation Common Stock's Earnings? | Return On Capital Employed
September 22, 2021
Benzinga Pro data, OncoCyte Corporation Common Stock (AMEX:OCX) reported Q2 sales of $2.03 million. Earnings fell to a loss of $13.57 million, resulting in a 19.44% decrease from...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.